



SOM Biotech appoints George G. Montgomery as Strategic Corporate Advisor

Barcelona, Spain, May 28th, 2024. SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent platform, has appointed George G. Montgomery as Strategic Corporate Advisor to the Board.

With over three decades of experience in health care, Mr. Montgomery has deep experience in start-ups (CFO and Board roles), principal investing and investment banking. In leadership roles at JPMorgan H&Q, Cowen and CSFB, he had extensive experience in public and private capital markets, M&A and partnering transactions.

Currently, Mr. Montgomery serves as CFO of Neuvogen, a next generation therapeutic cancer vaccine company. He is a Senior Advisor to ALTI Global, a leading global multi-family wealth management firm with approximately \$70 billion AUM. He serves on the Board of Ashvattha Therapeutics and chairs the Audit Committee too.

Mr. Montgomery also serves on the Board of the Jackson Laboratory and the Advisory Board for the Yale Cancer Center.

Raul Insa, CEO at SOM, and Silvia Panigone, Executive Chair, welcome George on board *“We are honored to have George on board; he will help the company to move forward with the next financing and to achieve international corporate goals. He adds great value to SOM team with his extensive experience in the corporate finance in private and public biotech and his impressive network”*.

“I look forward to working with the SOM team and Board at this exciting inflection point for the Company.” said Mr. Montgomery *“I appreciate the opportunity to work with Silvia and several of the Board members again and to make a difference for patients and their families.”*

About SOM Biotech: SOM Biotech (www.sombiotech.com) is a Spanish Headquartered biopharmaceutical company founded in 2009. It is based on a unique proprietary Artificial Intelligence (AI) platform (*SOM^{AI}PRO*[®]) to identify new Mechanism of Actions of small molecules drugs for the treatment of diseases with high unmet medical need with a focus on orphan disorders in the CNS space. *SOM^{AI}PRO*[®] is the only AI drug discovery platform which products achieved positive Phase II data in patients, demonstrating the high clinical predictive value of the platform. SOM leverage on an extensive pipeline of products developed for the treatment of orphan indications including TTR Amyloidosis, Huntington's disease, Phenylketonuria, Duchenne Muscular Dystrophy and Tardive Dyskinesia. The product for the treatment of Huntington Chorea is completing its Phase IIb study. A molecule to treat TTR Amyloidosis was licensed out upon positive Phase IIa data.

SOM is led by an experienced team with successful track record in both drug development and AI platforms development.

For more information about SOM Biotech, please contact: info@sombiotech.com